The Bajaj Healthcare Limited (BHL) has successfully developed and received approval from India’s drug regulator to distributed “Favijaj” tablet in the market to treat COVID-19 patients from May 4, 2021.
Pharmaceutical company Bajaj Healthcare Limited (BHL) has announced on Tuesday the launch of antiviral Favipiravir tablet with brand name “Favijaj”. The drug is used to treat patients suffering from influenza virus which has shown to be positive result to treat COVID-19 patients. The company has received an approval from India’s drug regulators to distribute the tablet “Favijaj” in the market for the treatment of patients suffering from COVID-19 infection from May 4, 2021 onward.
Favipiravir tablets, in various dosage forms of FAVIJAJ, are used for the treatment of mild to moderate COVID-19 disease, a regulatory filing outlines BHL. Favipiravir is an antiviral drug, which has shown potent in vitro activity against severe acute respiratory syndrome caused by COVID-19. The country’s drug controller allowed the supply of ‘Favijaj’ (Favipiravir) in the domestic and foreign markets.
Commenting on the launch of ‘Fawazaj’, joint managing director of Bajaj Healthcare, Anil Jain said, “We are delighted to include favipirvir in our growing product portfolio.
Anil Jain, Joit Managing Director of Bajaj Healthcare, has comented on the launch of “Favijaj”, “We are pleased to add Favipiravir to our growing product portfolios. The second wave is more aggressive and bigger in number than the first. We hope the availability of an effective treatment such as Favijaj will considerably ease the pressure, and offer patients much needed and timely therapy option”.
Bajaj Healthcare Limited has developed active pharmaceutical ingredient (API) and formulation for Favipiravir through its own in-house research and development (R&D) team. According to BHL, most patients with mild to moderate symptoms may benefit from the use of ‘ Favijaj ‘. ‘ Favijaj ‘ will be available as a prescription-based medicine with recommended doses.